Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

Beguelin, Charles; Suter, Annatina; Bernasconi, Enos; Fehr, Jan; Kovari, Helen; Bucher, Heiner C; Stoeckle, Marcel; Cavassini, Mathias; Rougemont, Mathieu; Schmid, Patrick; Wandeler, Gilles; Rauch, Andri; Calmy, Alexandra

doi:10.1111/liv.13528

Scientific article

English

Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

ContributorsBeguelin, Charles; Suter, Annatina; Bernasconi, Enos; Fehr, Jan; Kovari, Helen; Bucher, Heiner C; Stoeckle, Marcel; Cavassini, Mathias; Rougemont, Mathieu; Schmid, Patrick; Wandeler, Gilles; Rauch, Andri; Calmy, Alexandra

Published inLiver International, vol. 38, no. 3, p. 424-431

Publication date2018

Abstract

Hepatitis C virus (HCV) therapies with interferon-free second-generation direct-acting antivirals (DAAs) are highly effective and well tolerated. They have the potential to increase treatment eligibility and efficacy in HIV-infected patients. We assessed the impact of DAAs on treatment uptake and efficacy, as well as its impact on the burden of liver disease in the Swiss HIV Cohort Study (SHCS).

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

VIH/SIDA (930)

Citation (ISO format)

BEGUELIN, Charles et al. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. In: Liver International, 2018, vol. 38, n° 3, p. 424–431. doi: 10.1111/liv.13528

Article (Published version)

Identifiers

PID : unige:115506
DOI : 10.1111/liv.13528
PMID : 28741901

Journal ISSN1478-3223

459views

0downloads

Creation06/11/2018 16:35:00

First validation06/11/2018 16:35:00

Update time15/03/2023 16:03:42

Status update15/03/2023 16:03:42

Last indexation31/10/2024 13:04:19

Archive ouverte UNIGE

Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

Technical informations